Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H30O2S |
Molecular Weight | 358.537 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O
InChI
InChIKey=WUILNKCFCLNXOK-CFBAGHHKSA-N
InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
Molecular Formula | C22H30O2S |
Molecular Weight | 358.537 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Optical Activity | NONE |
Salirasib or S-trans,trans-Farnesylthiosalicylic acid (FTS) is a salicylic acid derivative with potential antineoplastic activity. It acts as a potent competitive inhibitor of the enzyme prenylated protein methyltransferase (PPMTase), which methylates the carboxyl-terminal S-prenylcysteine in a large number of prenylated proteins including Ras. In such systems, Salirasib inhibits Ras methylation but not Ras farnesylation. Salirasib selectively disrupts the association of chronically active Ras proteins with the plasma membrane. Salirasib competes with Ras for binding to Ras-escort proteins, which possess putative farnesyl-binding domains and interact only with the activated form of Ras proteins, thereby promoting Ras nanoclusterization in the plasma membrane and robust signals. Salirasib was studied in the clinical trials in patients with solid tumors, however its development was discontinued.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7731012
Curator's Comment: 1995
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4699 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7673206 |
2.6 µM [Ki] | ||
Target ID: GO:0007265 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Dislodgment and accelerated degradation of Ras. | 1998 Feb 3 |
|
Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. | 2000 Aug |
|
Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation. | 2008 Oct |
|
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. | 2011 Aug |
|
Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling. | 2012 Jun 28 |
Patents
Sample Use Guides
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Patients were treated with salirasib 800 mg twice daily on days 1 to 28 of a 35-day cycle. The schedule of days 1 to 28 of a 35-day cycle was chosen to allow initial imaging after 4 weeks of continuous treatment. After 10 patients were enrolled, because of toxicity (described in Results), the initial dose was changed to 600 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7673206
Salirasib or S-trans,trans-Farnesylthiosalicylic acid (FTS) inhibits the growth of human Ha-ras-transformed cells (EJ cells) and reverses their transformed morphology in a dose-dependent manner (0.1-10 microM). The drug does not interfere with the growth of cells transformed by v-Raf or T-antigen but inhibits the growth of ErbB2-transformed cells and blocks the mitogenic effects of epidermal and basic fibroblast growth factors, thus implying its selectivity toward Ras growth signaling, possibly via modulation of Ras-Raf communication.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:26:47 GMT 2023
by
admin
on
Fri Dec 15 16:26:47 GMT 2023
|
Record UNII |
MZH0OM550M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
231306
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/11/871
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
||
|
NCI_THESAURUS |
C1902
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5469318
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
SS-64
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
C71146
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
DTXSID501025654
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
100000177250
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
MZH0OM550M
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
162520-00-5
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
8825
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL23293
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY | |||
|
DB12681
Created by
admin on Fri Dec 15 16:26:47 GMT 2023 , Edited by admin on Fri Dec 15 16:26:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|